SurModics bolsters drug delivery IP; reports strong FY08
This article was originally published in Clinica
Executive Summary
SurModics has strengthened its drug delivery business after purchasing certain IP assets from PR Pharmaceuticals (PRP), a Fort Collins, Colorado-based specialist in injectable, biodegradable, sustained-release formulations. SurModics will gain PRP's protein delivery capabilities and its know-how in delivering injectable microparticles through smaller-gauge needles. The latter is used in ophthalmic applications – an area in which SurModics is particularly – as well as in subcutaneous or intramuscular injections. In addition to the IP, Eden Prairie, Minnesota-based SurModics will also take over several customer-paid development projects from PRP, as well as be a paid development partner for PRP's proprietary basal insulin product InsuLAR.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.